[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Tamura S, Ohkawauchi K, Yokoyama Y, Higashidani Y, Daibata M, Hiroi M, Yamamori S, Onishi S: Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract. J Gastroenterol; 2004 Oct;39(10):995-1000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
  • Mantle cell lymphoma (MCL) comprises 2.5%-7% of all non-Hodgkin's lymphomas, and the gastrointestinal tract is involved in about 20% of cases.
  • Multiple lymphomatous polyposis (MLP) is an uncommon disease that is regarded as the intestinal form of MCL.
  • We present a rare case of gastrointestinal MCL without MLP, and demonstrate that rituximab was effective for the treatment of this patient.
  • Small-to-medium size lymphoma cells were seen histologically from the tonsilla to the rectum.
  • The lymphoma cells were immunohistochemically positive for CD5, CD20, CD79a, and cyclin D1.
  • For treatment, the patient received a total of ten courses of combination chemotherapy consisting of cyclophosphamide (1000 mg), doxorubicin (70 mg), vincristine (2 mg) and prednisolone (50 mg) (CHOP), which led to a partial remission.
  • However, 2.5 years later, massive infiltrations of the lymphoma cells were found in the colon and stomach.
  • As the infiltrating lymphoma cells expressed CD20 molecules on their surfaces, the patient was treated with a chimeric anti-CD20 monoclohal antibody, rituximab, which showed significant efficacy, and a second partial remission was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Colonoscopy. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Remission Induction. Rituximab. Translocation, Genetic


2. Koh PK, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW: Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998). Int J Oncol; 2001 Apr;18(4):743-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998).
  • Extranodal non-Hodgkin's lymphoma (NHL) of the gastrointestinal tract accounts for about one third of all extranodal NHL.
  • We retrospectively reviewed the clinical and histopathologic records of 71 patients with stage IE and IIE primary gastrointestinal NHL referred to the Sheffield Lymphoma Group (SLG) from 1989 to 1998.
  • The most common primary site was the stomach (45 patients, 63% of all cases), followed by the small intestine (16, 23%) and large intestine (9, 13%).
  • Mucosa-associated lymphoid tissue (MALT) lymphomas were the largest histologic subtype seen (57%), with 87% of these arising from the stomach; next most frequent was the diffuse large B-cell subtype (21% of all cases) most frequently arising from the intestine (60%).
  • For treatment of gastric MALT lymphoma, a combined approach (surgery followed by chemotherapy, antihelicobacter therapy followed by chemotherapy) was favoured (22 cases).
  • Knowledge of the Revised European American Lymphoma classification and the Helicobacter pylori/MALT association has influenced treatment approaches over the 10-year study period.
  • For small intestinal lymphoma, surgery (with or without chemotherapy) gave 5- and 10-year survivals of 60%.
  • Overall survival of patients with primary gastrointestinal lymphoma managed by the SLG is similar to that reported from other large series.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Great Britain. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251169.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL: Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg; 2010 Jul;20(4):234-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel obstruction after treatment of intra-abdominal tumors.
  • BACKGROUND: Tumors of the solid viscera are one of the most common types of pediatric malignancies.
  • Due to the intra-abdominal location of many of these neoplasms, laparotomy and/or bowel resection are often necessary, predisposing patients to postoperative intestinal obstruction.
  • Additionally, chemotherapy and radiation therapy may lead to acute and chronic bowel injury, also potentially predisposing these patients to postoperative bowel obstruction.
  • METHODS: A retrospective data analysis of all patients diagnosed with intra-abdominal Wilms' tumor, rhabdomyosarcoma, neuroblastoma, and Hodgkin's and non-Hodgkin's lymphoma in a single institution from 1997 to 2007 was conducted.
  • Data collected included demographic factors, operations, incidence of small bowel obstruction (SBO) and the use of adjuvant or neoadjuvant chemoradiation therapy.
  • Patients who developed SBO were compared to those who did not develop obstruction.
  • Data comparisons were analyzed statistically using Fisher's exact test, 2-tailed Student's t-Test, or chi-square proportional analysis with significance reported for p<0.05.
  • Mean age at diagnosis was 8.1+/-5.8 years.
  • Tumor distribution was as follows: Wilms' tumor: 56 (19%); non-Hodgkin's lymphoma: 71 (24%); Hodgkin's lymphoma: 64 (22%); rhabdomyosarcoma: 32 (11%); and neuroblastoma: 68 (24%).
  • There were a total of 12 bowel obstructions in 11 patients (3.7%).
  • Children with bowel obstruction were more likely to be male (4.5:1, p=0.061) and younger (4.2 years versus 8.1 years; p=0.087).
  • Wilms' tumor accounted for 45% of patients with bowel obstruction, but made up only 19% of the study population.
  • The incidence of bowel obstruction in patients with Wilms' tumor was 8.9% compared to an overall incidence of 3.8% (p=0.043).
  • CONCLUSION: Bowel obstruction is relatively uncommon after intra-abdominal malignancies in children.
  • Wilms' tumor, rhabdomyosarcoma and Burkitt's lymphoma appear to be associated with the highest risk of bowel obstruction.
  • [MeSH-major] Abdominal Neoplasms / surgery. Intestinal Obstruction / etiology. Laparotomy / adverse effects

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496318.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B: Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J; 2002 Oct;43(5):555-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.
  • AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
  • METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period.
  • According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group.
  • RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients.
  • Six patients (8%) had multifocal disease.
  • Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%).
  • Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma.
  • Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy.
  • Eighteen patients (23%) experienced progressive disease.
  • Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005).
  • Patients with early-stage disease had significantly better OS and PFS than patients with advanced-stage disease (p=0.048).
  • CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems.
  • The main prognostic factors were primary tumor site and extent of the disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402395.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


5. Hata S, Pietsch J, Shankar S: Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma. Pediatr Hematol Oncol; 2004 Dec;21(8):707-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal complications in children undergoing chemotherapy for mediastinal non-Hodgkin's lymphoma.
  • Toxicities involving gastrointestinal tract are common in patients undergoing aggressive chemotherapy for cancer.
  • However, it is uncommon to develop severe ulceration or perforation of the small intestine in absence of direct involvement of the bowel with the malignancy.
  • The authors describe two children who developed severe gastrointestinal complications requiring surgical intervention following initial chemotherapy for non-Hodgkin's lymphoma.
  • Both patients had no evidence of small bowel involvement by lymphoma on clinical staging.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Intestinal Diseases / chemically induced. Lymphoma, Non-Hodgkin / complications. Mediastinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739625.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


6. Greco L, Maggi P, Ialongo P, Lospalluti M, Polizzi RA, Catalano G: Acute onset of non-Hodgkin's lymphoma with bowel perforation in a patient with over 15 years' HIV positivity. A case report. Chir Ital; 2002 Nov-Dec;54(6):893-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute onset of non-Hodgkin's lymphoma with bowel perforation in a patient with over 15 years' HIV positivity. A case report.
  • The authors report a rare case of acute onset of ileal non-Hodgkin's lymphoma with acute abdomen due to bowel perforation.
  • The patient had been on continuous, differentiated pharmacological treatment for the previous 5 years, and in the last month had had repeated episodes of fever with no clear aetiopathogenesis.
  • The patient was admitted as an emergency case with a picture of acute abdomen and was immediately operated on; ileal perforation due to multiple lymphomatous lesions in the small bowel was diagnosed.
  • The histological diagnosis was large-cell non-Hodgkin's lymphoma type B.
  • After the operation, the patient was treated by chemotherapy and, currently, after a 12-month follow-up, is in good general condition.
  • [MeSH-major] HIV Seropositivity / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Acute Disease. Adult. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613342.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


7. Tauro LF, Furtado HW, Aithala PS, D'Souza CS, George C, Vishnumoorthy SH: Primary lymphoma of the colon. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):279-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the colon.
  • Primary lymphoma of the colon is a rare tumor of the gastrointestinal (GI) tract and comprises only 0.2-1.2% of all colonic malignancies.
  • The most common variety of colonic lymphoma is non-Hodgkin's lymphoma (NHL).
  • The stomach is the most common location of GI lymphomas, followed by the small intestine.
  • Early diagnosis may prevent intestinal perforation; however, the diagnosis is often delayed in most cases.
  • Therapeutic approaches described in two subsets include: Radical tumor resection (hemicolectomy) plus multi-agent chemotherapy (polychemotherapy) in early stage patients, biopsy plus multidrug chemotherapy in advanced stage patients.
  • Radiotherapy is reserved for specific cases; surgery alone can be considered as an adequate treatment for patients with low-grade NHL disease that does not infiltrate beyond the sub mucosa.
  • Although resection plays an important role in the local control of the disease and in preventing bleeding and/or perforation, it rarely eradicates the lymphoma by itself.
  • Those with limited stage disease may enjoy prolonged survival when treated with aggressive chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Am J Surg. 2009 Jan;197(1):e11-2 [18723150.001]
  • [Cites] Int Surg. 2001 Jan-Mar;86(1):20-5 [11890335.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):291-7 [8071513.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):461-6 [8590847.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):22-33 [16502482.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1005-6; discussion 1006 [18565526.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):257-62 [10962456.001]
  • (PMID = 19794280.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981851
  •  go-up   go-down


8. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M, German Multicenter Study Group: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol; 2001 Sep 15;19(18):3861-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
  • PURPOSE: The study was initiated to obtain epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL).
  • Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.
  • Within the intestine, the small bowel and the ileocecal region were involved in 8.6% and 7.0% of the cases, respectively.
  • Forty percent of PGL were of low-grade mucosa-associated lymphatic tissue type.
  • Most intestinal NHL were germinal-center lymphomas.
  • In gastric and ileocecal lymphoma, event-free (EFS) and overall survival (OS) were significantly higher as compared with the small intestine or MGI (median time of observation, 51 months).
  • In PGL, localized disease was prognostic for EFS and OS.
  • Numbers in intestinal lymphomas were too small for subanalyses.
  • Larger studies are needed for stages III and IV and for intestinal NHL.
  • A uniform reporting system for PGI NHL, in terms of definitions and histologic and staging classifications, is needed to facilitate comparison of treatment results.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559724.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • RESULTS: Fourteen patients had primary involvement and 3 secondary.
  • Most patients had bulky disease: three had a diameter >5 cm and eight a diameter >10 cm.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Eleven patients underwent hemicolectomy: right sided in 9 and left sided in 2, and 5 DLBCL patients required emergency surgery for intestinal perforation.
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • Diagnosis is often delayed.
  • Early diagnosis may prevent perforation.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


10. Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M: Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy. Intern Med; 2005 May;44(5):476-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.
  • A 56-year-old man was admitted for treatment of non-Hodgkin's lymphoma (NHL).
  • He had undergone a partial small bowel and colon resection and had ileostomy due to bowel perforation induced by chemotherapy.
  • After the operation, his disease status was in partial remission (PR), and reduced-intensity allogeneic stem cell transplantation (RIST) was therefore performed for further improvement of disease status.
  • Graft-versus-host disease (GVHD) prophylaxis was performed using cyclosporin and short-term methotrexate.
  • [MeSH-major] Ileostomy. Intestinal Perforation / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Biopsy. Colon / radiography. Colon / radionuclide imaging. Colon / surgery. Follow-Up Studies. Humans. Male. Mediastinum / pathology. Mediastinum / radiography. Mediastinum / radionuclide imaging. Middle Aged. Positron-Emission Tomography. Rupture, Spontaneous. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942098.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • RESULTS: The most frequently site of the lesions in the 32 patients was the large intestine (n = 16, 50.0%), followed by small intestine (n = 8, 25.0%), ileocaecal region (n = 6, 18.8%) and multiple intestinal sites (n = 2, 6.2%).
  • Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response.
  • Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).
  • CONCLUSION: The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
  • [MeSH-major] Intestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • The major symptoms included abdominal pain and intestinal obstruction.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • Fourteen patients were treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and 8 patients were treated with Rituximab at the same time.
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies


13. Toffoli G, Corona G, Basso B, Boiocchi M: Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet; 2004;43(7):441-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic optimisation of treatment with oral etoposide.
  • Etoposide is a derivative of podophyllotoxin widely used in the treatment of several neoplasms, including small cell lung cancer, germ cell tumours and non-Hodgkin's lymphomas.
  • Oral administration of etoposide represents the most feasible and economic strategy to maintain effective concentrations of drug for extended times.
  • Nevertheless, the efficacy of oral etoposide therapy is contingent on circumventing pharmacokinetic limitations, mainly low and variable bioavailability.
  • Inhibition of small bowel and hepatic metabolism of etoposide with specific cytochrome P450 inhibitors or inhibition of the intestinal P-glycoprotein efflux pump have been attempted to increase the bioavailability of oral etoposide, but the best results were obtained with daily oral administration of low etoposide doses (50-100 mg/day for 14-21 days).
  • Pharmacokinetic parameters such as plasma trough concentration between two oral administrations (C(24,trough)), drug exposure time above a threshold value and area under the plasma concentration-time curve have been correlated with the pharmacodynamic effect of oral etoposide.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Etoposide / pharmacokinetics. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Area Under Curve. Biological Availability. Half-Life. Humans. Intestinal Absorption. Structure-Activity Relationship. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1607-9 [2170588.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2688-93 [679171.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):349-58 [11818199.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(6):367-72 [2469544.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):138-44 [7749790.001]
  • [Cites] Cancer Chemother Pharmacol. 1979;3(2):71-80 [389478.001]
  • [Cites] Drugs Aging. 2002;19(1):25-42 [11929325.001]
  • [Cites] J Clin Pharmacol. 2000 Feb;40(2):153-60 [10664921.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1427-35 [8021734.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16547-52 [11864976.001]
  • [Cites] Pharm Res. 1989 May;6(5):408-12 [2748532.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;31(5):350-6 [8431968.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Apr;18(4):377-80 [6889515.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 14):1-7 [1488650.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Oct;58(7):491-4 [12389073.001]
  • [Cites] Pharmacotherapy. 1999 Jan;19(1):101-7 [9917083.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1315-9 [3000790.001]
  • [Cites] J Pharm Sci. 1992 Mar;81(3):259-64 [1640365.001]
  • [Cites] Cancer Treat Rep. 1976 Sep;60(9):1295-1306 [1016966.001]
  • [Cites] Clin Pharmacokinet. 1997 Aug;33(2):103-21 [9260034.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(5):329-31 [2758563.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1480-6 [2072147.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):200-9 [7799021.001]
  • [Cites] Biochemistry. 1976 Dec 14;15(25):5443-8 [999819.001]
  • [Cites] Clin Pharmacol Ther. 1995 Jul;58(1):99-107 [7628187.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):363-7 [2994705.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 14):28-35 [1336897.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(10):546-54 [9393588.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1 Suppl 2):48-51 [3975657.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(7):427-33 [8188737.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2874-9 [1581902.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1179-88 [8388920.001]
  • [Cites] Cancer Treat Rep. 1976 Jul;60(7):943-5 [1009527.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1705-10 [9676845.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1101-7 [2348225.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2118-24 [9164226.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1613-7 [2170589.001]
  • [Cites] Eur J Cancer. 1993;29A(10):1479-81 [8398279.001]
  • [Cites] Cancer Treat Rep. 1978 Mar;62(3):473-5 [348319.001]
  • [Cites] J Clin Pharmacol. 1991 Dec;31(12):1155-60 [1662234.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;7(2-3):103-11 [7044591.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S118-26 [8070020.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(11):1816-22 [9470839.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):1-4 [7071607.001]
  • [Cites] Ann Oncol. 1998 Nov;9(11):1205-11 [9862051.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5929-33 [8261405.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2557-67 [9667278.001]
  • [Cites] Cancer Treat Rep. 1985 Mar;69(3):269-73 [3884152.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):259-67 [7908897.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 13):3-9 [1492225.001]
  • [Cites] Pharmacol Ther. 1991;49(3):283-92 [1675806.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1333-40 [2549204.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 13):34-44 [8996574.001]
  • [Cites] Toxicology. 2001 Feb 2;158(1-2):31-41 [11164990.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1739-53 [2213109.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(5):365-8 [2170043.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1592-7 [6572554.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(6):461-8 [10550566.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1690-5 [10430070.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Drugs. 1990 Mar;39(3):438-90 [2184009.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1992;13:75-82 [1389926.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):60-3 [8270985.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;35(5):432-6 [7850926.001]
  • [Cites] Cancer. 1977 Jul;40(1):334-42 [328129.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):125-33 [7497581.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):191-9 [7799020.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;19(1):16-20 [3815721.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):161-7 [7497587.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):396-401 [2918334.001]
  • [Cites] Mol Pharmacol. 1994 Feb;45(2):352-8 [8114683.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):265-9 [11685208.001]
  • [Cites] Clin Pharmacol Ther. 1975 Aug;18(2):221-6 [1157446.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1874-9 [2230875.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6854-6 [2208152.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 14):8-12 [1488657.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1468-74 [8021738.001]
  • [Cites] Eur J Cancer. 1994;30A(3):420-1 [8204376.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;7(2-3):127-31 [7083453.001]
  • [Cites] Biochemistry. 1976 Dec 14;15(25):5435-43 [999818.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):482-6 [8258198.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20 [3006680.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(4):316-22 [10071983.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S76-83 [8070032.001]
  • [Cites] Cancer. 1975 Apr;35(4):1141-4 [163675.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1986;3(2):95-9 [3018396.001]
  • [Cites] Cancer Treat Rep. 1985 Jan;69(1):69-72 [2981622.001]
  • [Cites] Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):677-83 [9923567.001]
  • [Cites] J Biol Chem. 1984 Nov 10;259(21):13560-6 [6092381.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;19(2):172-4 [3032470.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):247-56 [11165404.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2742-7 [10537337.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1871-9 [7636529.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300 [9732391.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(4):287-94 [10071979.001]
  • [Cites] Soc Sci Med. 1992 Dec;35(12):1505-9 [1283035.001]
  • [Cites] Cancer Treat Rep. 1979 Mar;63(3):485-7 [371801.001]
  • [Cites] Clin Pharm. 1989 Apr;8(4):274-93 [2653712.001]
  • [Cites] Int J Clin Pharmacol Res. 2000;20(1-2):21-30 [11146899.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):379-82 [6690051.001]
  • [Cites] Cancer Treat Rev. 1993;19 Suppl C:35-45 [8221715.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):292-6 [1310104.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2390-7 [7964955.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(4):273-8 [8324869.001]
  • [Cites] Arch Med Res. 1999 May-Jun;30(3):212-5 [10427872.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):117-24 [7497580.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):553-8 [8395871.001]
  • [Cites] Eur J Cancer. 1995;31A(4):622-6 [7576982.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):348-50 [1738188.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(6):506-12 [7554043.001]
  • [Cites] Cancer Treat Rev. 1993;19 Suppl C:27-33 [8221713.001]
  • [Cites] Drug Metab Dispos. 2002 Apr;30(4):457-63 [11901101.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(2):125-32 [9443625.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2039-41 [7857699.001]
  • [Cites] Br J Clin Pharmacol. 1991 Dec;32(6):669-70 [1768557.001]
  • [Cites] Eur J Cancer. 1991;27(1):28-30 [1849413.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):986-91 [8164052.001]
  • [Cites] Cancer Treat Rep. 1979 Aug;63(8):1231-9 [225026.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3109-13 [6539169.001]
  • [Cites] Ann Oncol. 1993 Jun;4(6):517-9 [8353095.001]
  • [Cites] Cancer Res. 1987 Sep 1;47(17):4658-62 [3621161.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(4):327-31 [8548877.001]
  • [Cites] Cancer Res. 1986 May;46(5):2566-71 [3697995.001]
  • [Cites] Pharmacol Rev. 1985 Jun;37(2):133-48 [3901045.001]
  • [Cites] N Engl J Med. 1982 May 6;306(18):1081-8 [7040951.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):177-84 [11319295.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):319-36 [7642466.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2319-30 [8572646.001]
  • [Cites] Br J Cancer. 1997;75(11):1660-6 [9184183.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(5):459-65 [8765440.001]
  • [Cites] Cancer Treat Rep. 1976 Sep;60(9):1377-9 [1016971.001]
  • [Cites] Cancer. 1991 Jan 1;67(1 Suppl):319-29 [1984835.001]
  • [Cites] Anticancer Drugs. 1999 Oct;10(9):815-9 [10587291.001]
  • [Cites] Xenobiotica. 1985 Apr;15(4):343-50 [4024669.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):361-6 [2155063.001]
  • [Cites] Br J Clin Pharmacol. 2001 Nov;52(5):511-9 [11736859.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1517-24 [9815952.001]
  • [Cites] Med Sci Monit. 2002 Sep;8(9):PI70-7 [12218955.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):317-27 [11699396.001]
  • [Cites] J Pharmacol Exp Ther. 1992 May;261(2):491-6 [1578365.001]
  • [Cites] Br J Clin Pharmacol. 2000 Oct;50(4):315-24 [11012554.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S101-4 [8070017.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1973 Sep;81(5):715-24 [4771975.001]
  • [Cites] Eur J Cancer. 1990;26(7):818-21 [2145902.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5232-7 [9393740.001]
  • [Cites] Br J Cancer. 1997;76(11):1500-8 [9400949.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;20(1):59-66 [3621455.001]
  • [Cites] Clin Pharmacol Ther. 1989 Jan;45(1):49-55 [2910637.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(5):339-42 [1312906.001]
  • [Cites] Clin Pharmacol Ther. 1991 Oct;50(4):385-93 [1914374.001]
  • [Cites] Clin Pharmacol Ther. 1994 Nov;56(5):503-11 [7955814.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 14):25-7 [1488652.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;14(2):104-7 [3971474.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;7(2-3):141-5 [7083454.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1602-8 [8336196.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):719-25 [9815741.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1690-5 [3772420.001]
  • [Cites] J Natl Cancer Inst. 1990 Dec 19;82(24):1899-903 [2174464.001]
  • [Cites] N Engl J Med. 1985 Mar 14;312(11):692-700 [2983208.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Jul 18;122(1):165-70 [6331440.001]
  • [Cites] Anticancer Drugs. 1999 Oct;10(9):807-14 [10587290.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(2):141-6 [8616904.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):5-15 [1988106.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5692-5 [3167829.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):374-7 [8426216.001]
  • [Cites] Lancet. 1981 Oct 24;2(8252):912-5 [6117692.001]
  • [Cites] Med Oncol. 2001;18(4):269-75 [11918453.001]
  • [Cites] Anticancer Drugs. 2001 Mar;12(3):267-73 [11290874.001]
  • [Cites] J Clin Invest. 1987 Oct;80(4):1029-36 [3654968.001]
  • (PMID = 15139794.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 178
  •  go-up   go-down


14. Novakovic BJ, Novakovic S, Frkovic-Grazio S: A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep; 2006 Jul;16(1):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas.
  • Intestinal T cell lymphomas are rare, but highly aggressive in their clinical course.
  • Generally diagnosed in advanced stages and presenting as surgical emergencies, they also respond poorly to standard anti-lymphoma therapies.
  • Since these lymphomas are still not well characterized, we aimed our retrospective research at the evaluation of clinical features and treatment response in patients with intestinal T cell lymphomas diagnosed between February 1996 and November 2004.
  • Details of history, physical examination, staging investigation, treatment and outcome were taken from patient records.
  • Ten (67%) patients had enteropathy-associated T cell lymphoma (EATL) and 5 (33%) had peripheral T cell lymphoma (PTCL).
  • Surgery was performed on 11 patients with 8 cases on an emergency basis; all visible disease was resected in only 3 patients.
  • In the continuation of treatment, all 15 patients received chemotherapy (predominantly CHOP).
  • Six patients were treated with field radiotherapy as a part of the first treatment.
  • In total, complete response was achieved in 6 patients (40%) with a median duration of 5.3 months (range, 2 to 12 months), stable disease in 3 patients (20%), and progressive disease in 6 patients (40%).
  • Results were better in patients with limited disease.
  • The most frequent treatment complications were small bowel perforation, obstruction, gastrointestinal bleeding, and infection.
  • Even though some patients underwent second- and third-line treatment, 13 (87%) of the total 15 patients died from progressive disease or complications of treatment.
  • The prognosis and standard treatment of patients with intestinal T cell lymphomas are unsatisfactory with only a few long-term survivors.
  • Therefore, earlier diagnosis and the development of more effective treatments are urgently required to improve the prospects of these patients.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786145.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Kella VK, Constantine R, Parikh NS, Reed M, Cosgrove JM, Abo SM, King S: Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature. World J Surg Oncol; 2009;7:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature.
  • BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node.
  • Extra nodal involvement is present in the majority of cases, with a peculiar tendency to invade the gastro-intestinal tract in the form of multiple lymphomatous polyposis.
  • Few cases of mantle cell lymphoma presenting with intussuception have been reported.
  • Here we present a rare case of multiple intussusceptions caused by mantle cell lymphoma and review the literature of this disease.
  • The histology and immuno-histochemistry of the excised small and large bowel revealed mantle cell lymphoma with multiple lymphomatous polyposis and positivity to Cyclin D1 marker.
  • The patient was successfully treated with Rituximab-CHOP chemotherapy and remains in complete remission at one-year follow-up.
  • CONCLUSION: This is a rare case of intestinal lymphomatous polyposis due to mantle cell lymphoma presenting with multiple small bowel intussusceptions.
  • Our case highlights laparoscopic-assisted bowel resection as a potential and feasible option in the multi-disciplinary treatment of mantle cell lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / complications. Ileal Diseases / etiology. Intussusception / etiology. Lymphoma, Mantle-Cell / complications


16. Khomov DA, Sinev IuV, Sotnikov VM: [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy]. Vestn Rentgenol Radiol; 2008;(2-3):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy].
  • The paper describes the experience in using capsule endoscopy to diagnose small bowel lesions during and after chemoradiation therapy in patients with diagnosed Hodgkin's lymphoma and an attempt to compare the current views of normal tissue response to ionizing radiation, as well as drugs used for chemotherapy.
  • [MeSH-major] Capsule Endoscopy. Hodgkin Disease / therapy. Intestinal Diseases / pathology. Intestine, Small / pathology
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21337763.001).
  • [ISSN] 0042-4676
  • [Journal-full-title] Vestnik rentgenologii i radiologii
  • [ISO-abbreviation] Vestn Rentgenol Radiol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Salemis NS, Tsiambas E, Liatsos C, Karameris A, Tsohataridis E: Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course. J Gastrointest Cancer; 2010 Dec;41(4):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course.
  • Symptoms and signs are often vague and non-specific making a preoperative diagnosis difficult.
  • The purpose of this study is to present a rare case of a jejuno-jejunal intussusception due to primary intestinal non-Hodgkin's lymphoma in a patient with an unusual clinical course.
  • Computed tomography scan and ultrasonography findings were suggestive of small bowel intussusception.
  • RESULTS: Laparotomy revealed a jejuno-jejunal intussusception caused by a primary B cell non-Hodgkin's lymphoma 20 cm distal to the ligament of Treitz.
  • The patient refused postoperative adjuvant chemotherapy.
  • Seven months later, he presented with upper gastrointestinal bleeding, and the diagnostic evaluation revealed gastric infiltration of large B cell non-Hodgkin's lymphoma.
  • Despite chemotherapy, he died of disseminated progressive disease 7 months later.
  • CONCLUSIONS: Adult jejuno-jejunal intussusception due to primary non-Hodgkin's lymphoma is a rare clinical entity.
  • Appropriate investigations can lead to a prompt preoperative diagnosis.
  • Resection without prior reduction is the treatment of choice.
  • Our patient's refusal of postoperative adjuvant chemotherapy likely resulted in relapse of the disease in another part of the gastrointestinal tract.
  • [MeSH-major] Intussusception / etiology. Jejunal Neoplasms / complications. Jejunal Neoplasms / pathology. Lymphoma, B-Cell / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):339-44 [15101721.001]
  • [Cites] Int J Hematol. 2008 May;87(4):375-81 [18409078.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] Radiol Clin North Am. 2008 Mar;46(2):287-312, ix [18619382.001]
  • [Cites] J Gastrointest Cancer. 2009;40(3-4):79-82 [19937400.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):45-7 [10652920.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):230-6 [7469558.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):834-9 [15951987.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):406-15 [17593870.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):343-7 [12612513.001]
  • (PMID = 20411355.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chen CQ, Yin L, Peng CH, Ye M, Zhao R, Chen GM, Zhou HJ, Li HW, Fan YZ: [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):693-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
  • OBJECTIVE: To investigate the clinicopathological features of primary diffuse large B-cell lymphomas (DLBCLs) of the small intestine, CD10 expression, and their relationship to prognosis.
  • METHODS: Twenty-four cases of small intestinal DLBCLs were studied clinically and pathologically.
  • All cases were staged according to the Ann Arbor classification of lymphoma.
  • Twenty cases (83.3%) received surgical resection, sixteen cases (66.7%) received chemotherapy, and no patient received radiotherapy.
  • Although there was no statistically significant difference(P = 0.28) in therapy result between the CD10+ and CDO1--groups, patients with CD10+ lymphoma more frequently presented with stages I compared with those with CD10 - lymphoma (P = 0.013).
  • Five cases died of the disease.
  • CONCLUSION: The primary small intestnal diffuse large B cell lymphoma patients at stage I and II respond better to therapy including surgical resection and chemotherapy than those at stage III and IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms. Intestine, Small / surgery. Lymphoma, Large B-Cell, Diffuse. Neprilysin / metabolism
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Praveen S, Ho CC, Fadilah S, Sagap I: Clinical Characteristics and Treatment Outcome of Gastrointestinal Non-Hodgkin's Lymphoma. Med J Malaysia; 2010 Jun;65(2):98-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical Characteristics and Treatment Outcome of Gastrointestinal Non-Hodgkin's Lymphoma.
  • Primary gastrointestinal (GIT) lymphoma constitutes only 5 - 10% of all gastrointestinal tumours.
  • The optimal therapy for these lymphomas is poorly defined and still controversial.
  • We present our experience in the treatment and outcome of primary GIT lymphomas in UKM Medical Center, Malaysia.
  • A retrospective review of all patients with primary GIT lymphoma from the year 2002 until 2007 was done.
  • Our series has shown that primary GIT lymphoma is a rare disease as it comprises only 6.5% of all lymphomas treated in this institution.
  • We had a female predominance of this disease with a large majority at an advanced stage of the disease.
  • There was equal distribution involving stomach, small and large intestines.
  • The incidence of primary GIT lymphomas was 6.5% with a female predominance.
  • The majority had advanced diseases (stage III and IV) with equal distribution involving the stomach, small and large intestines.
  • The most common histological variant was diffuse large B cell lymphoma (66%).
  • Most (83%) patients with intestinal lymphoma had surgical resection and adjuvant chemotherapy.
  • All patients with gastric lymphomas had chemotherapy alone.
  • The mortality rate was 22% predominantly in younger patients with aggressive histology subtypes and advanced disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Treatment Outcome
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Lymphoma, Large B-Cell, Diffuse. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23756789.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down






Advertisement